Disclosures for "BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson’s Disease Mouse Model"
-
Dr. Liang has received personal compensation for serving as an employee of Highlightll. Dr. Liang has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Highlightll. Dr. Liang has stock in Highlightll. Dr. Liang has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Tang has nothing to disclose.
-
Ms. Shankar has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Transcenta Therapeutics.
-
Dr. Car has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Car has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PathAI. Dr. Car has stock in BHVN. Dr. Car has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Qureshi has received personal compensation for serving as an employee of Biohaven. Dr. Qureshi has stock in Biohaven Pharmaceuticals.
-
Author has nothing to disclose
-
Dr. Lair has received personal compensation for serving as an employee of Biohaven. An immediate family member of Dr. Lair has received personal compensation for serving as an employee of CVS Health. An immediate family member of Dr. Lair has received personal compensation for serving as an employee of PPD/Thermo Fisher Scientific. Dr. Lair has stock in Biohaven. An immediate family member of Dr. Lair has stock in Aetna/CVS. An immediate family member of Dr. Lair has stock in PPD/Thermo Fisher Scientific. Dr. Lair has a non-compensated relationship as a Board Member with NY State Neurological Society that is relevant to AAN interests or activities.